Sector News

After NICE setback, Roche strikes deal for Gazyvaro coverage in U.K.

July 27, 2017
Food & Drink

After sparring with England’s cost gatekeepers on several occasions, Roche has sealed a deal to provide Gazyvaro to U.K. patients through the revamped Cancer Drugs Fund. Under the arrangement, it’s estimated 600 relapsed refractory follicular lymphoma patients will have access to the blood cancer drug each year.

To be given in combo with chemotherapy and after treatment with Roche’s Rituxan, Gazyvaro will be available for up to four years as authorities gather more data on its long-term cost effectiveness. The Cancer Drugs Fund is a second-line program for drugs that don’t make it past an initial review at NICE.

The deal is contingent on a confidential discount, according to a final appraisal document.

In a statement, Roche U.K. general manager Richard Erwin said the decision is “encouraging in terms of the flexibility of the new NICE and Cancer Drugs Fund system, where collecting the right data across a realistic time frame, in this case four years, is the key to demonstrating the value of Gazyvaro in the long-term.”

“We have worked tirelessly with NICE to ensure that those patients who need Gazyvaro can receive it and we are delighted with this outcome,” Erwin added.

Roche has had somewhat of a contentious past with NICE as budget problems have forced the cost regulator to get tough on approving innovative new meds. The Swiss drugmaker has been among the pharma companies to criticize the regulator’s review methodology, and last summer the company critiqued an overhaul of the beleaguered Cancer Drugs Fund.

Last year, NICE and NHS England took over the CDF in response to budget overruns at the fund that created coverage concerns for dozens of expensive cancer drugs. Erwin said the process “could mean that thousands more cancer patients are denied medicines their doctors believe could be effective in their treatment.”

Before the overhaul, also due to cost issues, CDF stopped covering 16 medications, including Roche breast cancer treatment Kadcyla. At the time, Roche CEO Severin Schwan called the decision “stupid” and “completely arbitrary.”

NICE held up another of the drugmaker’s breast cancer drugs, Perjeta, for years before ultimately recommending the med for routine coverage in November.

Source: FiercePharma

By  Eric Sagonowsky

comments closed

Related News

November 27, 2022

Cargill to appoint Brian Sikes as president and CEO

Food & Drink

Cargill will appoint Brian Sikes as its president and chief executive officer on 1 January 2023. The soon-to-be CEO, currently holding the chief operating officer title, has worked at Cargill for 31 years. Dave MacLennan, who has served as Cargill’s CEO since 2013, will assume the role of executive chair of the company’s board of directors.

November 27, 2022

Wellness, self-expression drive the latest trends in colors and flavors

Food & Drink

Comforting colors, feel-good flavors, and unique food and beverage experiences will resonate most with consumers in the new year, according to ADM’s latest Flavor and Color Outlook. ADM anticipates that 2023 will be the year of self-expression, and the company identified four trends that are sure to stand out.

November 27, 2022

Nespresso unveils home-compostable coffee capsules in partnership with Huhtamaki

Food & Drink

Nestlé’s Nespresso brand will pilot home-compostable coffee capsules on the Nespresso Original system in France and Switzerland from spring 2023 before further launches in several other European countries within a year. The paper-based capsules are touted as a breakthrough in packaging technology after three years of R&D.